Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $22.0 million.

  • Lifecore Biomedical's Accumulated Expenses fell 2.57% to $22.0 million in Q2 2025 from the same period last year, while for May 2025 it was $22.0 million, marking a year-over-year decrease of 2.57%. This contributed to the annual value of $22.0 million for FY2025, which is 2.57% down from last year.
  • According to the latest figures from FY2025, Lifecore Biomedical's Accumulated Expenses is $22.0 million, which was down 2.57% from $22.5 million recorded in FY2024.
  • Lifecore Biomedical's Accumulated Expenses' 5-year high stood at $22.5 million during FY2024, with a 5-year trough of $4.1 million in FY2023.
  • For the 3-year period, Lifecore Biomedical's Accumulated Expenses averaged around $16.2 million, with its median value being $22.0 million (2025).
  • In the last 5 years, Lifecore Biomedical's Accumulated Expenses plummeted by 53.64% in 2023 and then soared by 443.74% in 2024.
  • Lifecore Biomedical's Accumulated Expenses (Yearly) stood at $7.5 million in 2021, then climbed by 19.21% to $8.9 million in 2022, then crashed by 53.64% to $4.1 million in 2023, then skyrocketed by 443.74% to $22.5 million in 2024, then dropped by 2.57% to $22.0 million in 2025.